Clinical trial with subdermal implants of the progestin R-2323

      This paper is only available as a PDF. To read, Please Download here.


      Six 3-cm polydimethylsiloxane capsules containing 30 mg each of R-2323 were implanted subdermally in each of 38 women to assess their effect upon fertility, menstrual pattern, some aspects of metabolism and the incidence of side effects associated with the use of this hormonal contraceptive. There were no pregnancies in a total of 292 months of exposure. The longest duration of use was 12 months and the median was between 8 and 9 months. Amenorrhea and signs of androgenicity such as acne and hyperthricosis were common complaints and a frequent reason for closure. Headache and nervousness also were reported by a high proportion of patients. Blood and urine analyses were normal with the exception of elevated transaminases in 20 out of 27 patients after the third month of treatment. Side effects and elevation of the serum transaminase levels disappeared promptly after removal of the implants in all cases. It is concluded that R-2323 implants at the dose tested are potent inhibitors of fertility in women. The high incidence of treatment-associated adverse reactions impose limitations on their use in Chilean women.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Contraception
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. Croxatto, H.B. and Diaz, S. Contraception in women with steroid implants. Excerpta Medica Internat. Series, In press.

        • Croxatto H.B.
        • Diaz S.
        • Quinteros E.
        • Simonetti L.
        • Kaplan E.
        • Rencoret R.
        • Leixelard P.
        • Martinez C.
        Clinical assessment of subdermal implants of megestrol acetate, d-norgestrel and norethindrone as a long-term contraceptive in women.
        Contraception. 1975; 12: 615
        • Coutinho E.M.
        • Da Silva A.R.
        One year contraception with norgestrienone subdermal silastic implants.
        Fertil. Steril. 1974; 25: 170
        • Coutinho E.M.
        • Da Suva A.R.
        • Carreira C.M.
        • Chaves M.C.
        • Filho J.A.
        Contraceptive effectiveness of silastic implants containing the progestin R-2323.
        Contraception. 1975; 11: 625
        • Hill R.
        • Dumas K
        The use of dogs for studies of toxicity of contraceptive hormones.
        Acta Endocr. (Kbh) suppl. 1974; 185: 74-89
        • Nelson L.W.
        • Carlton W.W.
        • Weikel J.H.
        Canine mammary neoplasms and progestogens.
        J.A.M.A. 1972; 219: 1601-1606
        • Marinovic I.
        • Guerra C.
        • Larach G.
        Incidencia de litiases biliar en material de autopsias y analisis de la composicion de los calculos.
        Rev. Med. Chile. 1972; 100: 1320-1327
        • Newman H.F.
        • Northrup J.
        The autopsy incidence of gallstones.
        International Abstract of Surgery. 1959; 109: 1-13
        • Reyes H.
        • Radrigan M.E.
        • Schramm G.
        • Katz R.
        Frecuencia de ictericia y prurito idiopatico del embarazo en mujeres chilenas.
        Rev. Med. Chile. 1968; 96: 409-414
        • Mery A.
        • Iturriaga S.
        • Leal G.
        • Munoz W.
        Pruebas de la funcion hepatica durante el trabajo de parto.
        in: Relatos de XIII Congreso Chileno de Obstetricia y Ginecologia, Santiago28 Noviembre, 1969: 415-416
        • Herrera M.
        • De la Fuente S.
        • Ugarte G.
        • Lorca F.
        Las transaminasas en el embarazo prolongado.
        Rev. Chil. Obstet, y Ginec. 1962; XXVII: 141-148